You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
Sarcopenia in COPD
  1. Simone Scarlata1,
  2. Matteo Cesari2,3,
  3. Raffaele Antonelli Incalzi1
  1. 1Chair of Geriatrics, Unit of Respiratory Pathophysiology, Campus Bio Medico University and Teaching Hospital, Rome, Italy
  2. 2Gérontopôle, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
  3. 3Institut national de la santé et de la recherche médicale (UMR1027), Université de Toulouse III Paul Sabatier, Toulouse, France
  1. Correspondence to Professor Matteo Cesari, Gérontopôle, Centre Hospitalier Universitaire de Toulouse, 37 Allées Jules Guesde, 31000 Toulouse, France; macesari{at}gmail.com

https://doi.org/10.1136/thoraxjnl-2015-206929

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Dear Editor,

    We read with great interest the paper by Jones et al1 about the prevalence, clinical correlates and response to pulmonary rehabilitation of sarcopenia in COPD.

    We believe that authors have meritoriously focused their attention on a highly relevant topic, which is the skeletal muscle decline in patients with COPD. Sarcopenia represents a condition exposing older persons to the risk of disability and negative health-related outcomes. Since respiratory conditions, including COPD, may directly (eg, through poor peripheral oxygenation, inflammation, hypercatabolic state) and indirectly (eg, inducing sedentary behaviours) affect the skeletal muscle, more attention should be given to sarcopenia. This implicitly suggests the need …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; externally peer reviewed.